Visualizing hypoxic tumor regions is important for improving cancer treatment, and hypoxia positron emission tomography has been shown to be a promising tool. The tumor uptake of 3 clinical hypoxia PET , in a preclinical tumor model. Tracer uptake was evaluated for the optimal time point for imaging, tumor-to-blood ratios (TBR), spatial reproducibility, and sensitivity to oxygen modification. Methods and Materials: PET/computed tomography (CT) images of rhabdomyosarcoma R1-bearing WAG/Rij rats were acquired at multiple time points post injection (p.i.) with one of the hypoxia tracers. TBR values were calculated, and reproducibility was investigated by voxel-to-voxel analysis, represented as correlation coefficients (R) or Dice similarity coefficient of the high-uptake volume. Tumor oxygen modifications were induced by exposure to either carbogen/nicotinamide treatment or 7% oxygen breathing. Conclusions: This study indicates that each tracer has its own strengths and, depending on the question to be answered, a different tracer can be put forward. Ó 2015 Elsevier Inc.
Introduction
Tumor hypoxia is an important factor in worsening cancer patients' treatment outcome. Regions of low oxygen concentration are a well-known characteristic of solid tumors and can be caused by impaired blood vessel development, temporal occlusions of blood vessels, or excessive tumor growth (1, 2) . Knowledge of the extension and location of hypoxia would provide additional information that could be integrated into strategies of conventional treatments, potentially leading to improved therapeutic outcome (3) . Positron emission tomography (PET) has been shown to be a suitable, noninvasive, 3-dimensional imaging technique for the detection of hypoxic tumor regions. PET tracers containing the oxygen-sensitive nitroimidazole group are specifically designed to detect hypoxic regions, and the feasibility of these tracers has been studied extensively in several independent clinical and preclinical studies (1) . 18 F-labeled fluoromisonidazole ([ 18 F]FMISO) was the first specific hypoxia PET tracer and, although it may be the most frequently used tracer for this purpose, its suitability is limited because of slow tumor-specific accumulation and nonspecific washout (4) . Second-generation 2-nitroimidazole tracers with different clearance and hydrophilicity characteristics have been developed in an attempt to overcome these disadvantages, [ ]FMISO PET imaging, using different experimental setups, tumor models, and acquisition protocols (5) (6) (7) (8) . Next, the third-generation hypoxia tracer [ 18 F]flortanidazole (HX4) was developed and evaluated in a preclinical rhabdomyosarcoma tumor model, where it was found to be dependent on tumoral oxygenation status (9 (FDG) in a preclinical tumor model. We investigated the uptake of each tracer over time and determined the tumor-to-background ratios. A second PET scan was performed on the same animal after 48 hours to assess spatial reproducibility. Furthermore, tracer uptake was challenged by exposing the animals to modified oxygen concentrations. The focus of this study was to investigate the performance and characteristics of the different hypoxia PET tracers, using the same tumor model.
Methods and Materials
Tracer synthesis, tumor model, experimental design 
Image acquisition and analysis
Images were acquired and analyzed using a clinical PET/ CT scanner (Siemens Biograph 40; Siemens Healthcare) and dedicated software (TrueD VC60; Siemens) as described in more detail in online supplementary material (available online at www.redjournal.com) and previously (9) . Tumor-to-blood ratios (TBR) and tumor-to-muscle ratios (TMR) were determined using heart and muscle of the hind leg as background tissue, respectively. Spatial reproducibility scans were performed in the same animal within short time frames, using rigid registration voxel-to-voxel analysis (from 2 to 6 hours post injection [p. ). Furthermore, a voxel-wise comparison of the 2 scans was performed for which a correlation coefficient was calculated. Imaging schedules for oxygen modification using either nicotinamide (500 mg/kg, intraperitoneal) and carbogen (95% O 2 , 5% CO 2 ; flow Z 5 L/min) or 7% oxygen (residual N 2 flow Z 2.5 L/min) breathing are shown in Figure 1B . In short, after injection of the tracer, the first basal scan was performed at 2 hours p.i., followed by oxygen modification treatment and a second scan at 5 hours p.i.
Statistics
Prism version 5.01 software (GraphPad) for Windows (Microsoft) was used to perform statistical analyses. To determine the statistical significance of differences between 2 independent groups of variables, we used the nonparametric Mann-Whitney U test for small groups. Spatial reproducibility was analyzed using either a Dice similarity coefficient for the calculation of the overlap fractions or Pearson correlation for voxel comparison. P values of <.05 were assumed to be significant.
Results
PET/CT imaging was performed to assess tracer accumulation over time for the 4 different tracers, using a dynamic imaging schedule ( Fig. 1 A and B) . Each tracer had a different accumulation pattern within the tumor, represented by maximum (SUV max ; Fig. 2A ) and mean (SUV mean ; Fig. E1A ; available online at www.redjournal.com) standardized uptake values, whereas blood and muscle tracer uptake exhibited similar patterns. Due to clearance of the nonspecific binding and specific trapping in hypoxic tumor regions, all TBRs were greater than 1 ( Fig. 2B and Fig. E1B ; available online at www.redjournal.com). Furthermore, clearance rates for heart and muscle were comparable, giving a muscle to blood ratio around unity ( Fig. E1D; (Fig. 2C and Fig. E1C ; available online at www.redjournal.com).
Uptake images from 2, 3, 4, and 5 hours p.i. were compared to the 6-hour p.i. scan to perform a voxel-to-voxel comparison of absolute tumor uptake. A correlation coefficient was calculated from the 2 scans (Fig. 3A) . Averaged correlation coefficients demonstrated a stable uptake pattern in the tumor for all investigated tracers over short time periods (up to 6 hours) (Fig. 3B) (Fig. 3C) . To further investigate spatial reproducibility, we calculated an overall Dice similarity coefficient in which the high uptake region as a percentage of the total tumor volume from the first scan was compared to the same percentage of total volume area from a second scan (Fig. 3D) . This analysis showed a high reproducibility for (Fig. 3E) .
Rats were exposed to 7% oxygen breathing (Fig. 1B) the tumor compared to that in untreated animals (Fig. 4A) (Fig. 4A) . When the effect of maximal tumor uptake on increased hypoxia was studied, no significant effects were observed, although there was a trend toward increased uptake of [ 18 F]HX4 in the tumor ( Fig. E2A ; available online at www.redjournal.com).
The reversibility of tracer uptake on tumor reoxygenation was examined by treating the rats with nicotinamide Fig. 4 . Oxygen modification. Relative SUV mean and tracer ratios compare untreated rats (basal) with those breathing 7% oxygen (7% oxygen) (A) and those receiving nicotinamide/carbogen (carbo) treatment (B Z maximum standard uptake value; TBR Z tumor-to-blood ratio; TMR Z tumor-to-muscle ratio. and carbogen (Fig. 1B) . Relative SUV mean ( Fig. E1A The rat rhabdomyosarcoma R1 model with a large hypoxic fraction (18) was chosen to ensure sufficient visualization of the uptake of hypoxia tracers using a preclinical model on a clinical PET/CT scanner. Although some variation in tumor volume was seen, the hypoxic fraction was shown to be stable within the tumor model (18) . PET acquisition was performed from the time of injection until 6 hours p.i. to determine the optimal uptake in the tumor and highest TBR. In this study, we found the most optimal TBR for [
18 F]FAZA at 2 hours p.i. This finding is consistent with clinical studies in head and neck squamous cell carcinoma and nonesmall-cell lung cancer (NSCLC), where imaging at 4 hours p.i. did not improve the TBR compared to 2 hours p.i. (19) (20) (21) . [ 18 F]HX4 showed an optimal TBR at 3 hours p.i., which was also observed in an NSCLC patient study where image contrast did improve from 2 to 4 hours p.i. (22) . As clinically demonstrated, [ 18 F]FMISO does not show plateau formation and has better TBR at later time points (23) , which was also observed in this preclinical study. Comparative studies already have indicated that [ 18 F]HX4 imaging in head and neck cancer patients at 1.5 hours p.i. was found to have TMR properties similar to those of [ 18 F]FMISO at 2 hours p.i. (24) . This is also reflected in the biological half-life of the tracers, which is much higher in normal tissue for [ 18 18 F]FAZA (preclinical: 2.8 hours). The findings from this preclinical study are in line with those from available clinical studies, and although caution needs to be taken in extrapolation of the data, this might indicate that the results found here in this animal model can be translated to some extent to the clinical setting.
One disparity between clinical and preclinical studies is the use of anesthetic drugs. In this study, pentobarbital was used, and although it was shown that this causes a reduction in the radioactivity in blood and muscle, it did not influence tracer uptake in the tumor, nor did it lead to a significant change in tumor-to-background ratios (25) .
The ultimate goal of tumor hypoxia imaging is to improve treatment outcome either by detecting hypoxia to aid in the decision to add specific antihypoxia drugs or by adapting radiation therapy using image guidance. Considering that hypoxia imaging can be used to generate personalized intensity modulated radiation therapy plans in which these radiation-resistant parts of the tumor can be boosted (26, 27) , it would be desirable to have a tracer that shows stable uptake over time so that a single scan could be used for several days of treatment. Voxel-to-voxel analyses resulted in high reproducibility for all tracers within a 6-hour scan. Examining spatial reproducibility by comparing a high uptake region revealed good overlap between 2 consecutive scans 48 hours apart for [ 18 (28) . However, voxel-to-voxel analysis of [ 18 F]FMISO uptake over a 3-day interval found a correlation of the hypoxic distribution in less than 50% of the head and neck cancer patients (29) . [ 18 F]FMISO in the same patient population and during chemoradiation therapy showed a stable conformation of the hypoxic subvolumes (30) . Our data show that reproducibility of [
18 F]FAZA is poor after 48 hours, even without additional anticancer treatment. This is surprising given the fact that all investigated hypoxia tracers are based on the same nitroimidazole trapping mechanism. Contradictions in [
18 F]FAZA reproducibility are observed between different preclinical and clinical studies, which might also be caused by the differences in metabolism among organisms. Preclinical micro-PET analysis of [
18 F]FAZA uptake showed voxel-to-voxel reproducibility between 2 baseline scans performed 24 hours apart; even after fractionated radiation therapy, a fairly stable intratumoral tracer distribution was observed (31) . However, in a clinical trial, [ 18 F]FAZA uptake was evaluated after several rounds of radiation therapy treatment and hypoxic regions were found not to be in the same location (19 Because tumor hypoxia is a dynamic process that consists of both chronic and acute hypoxia, a tumor's oxygen status changes continuously, and most hypoxia tracers mainly detect the chronic hypoxic fraction. However, there are suggestions that acute hypoxia also plays a prominent role in determining the treatment outcome (32) . Changing a tumor's oxygen status by clamping or reduced oxygen breathing mimics this dynamic process and gives the opportunity to study the behavior of tracer uptake under these conditions. In the ideal situation, one would wish a hypoxia tracer to rapidly and specifically accumulate in the hypoxic regions with fast clearance in the nonhypoxic tissues. Binding of the tracer would be irreversible, and no circulating free available tracer would be present.
Previous studies have shown that a treatment combining nicotinamide and carbogen increases a tumor's oxygen status (9, 33) , whereas 7% oxygen breathing increases the hypoxic fraction (9) . In this study, the oxygen modification was applied only 2.5 hours after tracer injection. Increasing the hypoxic fraction during tracer accumulation is dependent on the presence of unbound, circulating tracer. For all hypoxia tracers, circulating tracer was present after 3 hours, based on the measured activity in the blood (SUV of 2.4 for [ 18 showed increased uptake in the tumor after 7% oxygen breathing. This effect was observed mainly in the mean values rather than in the maximum values, indicating that the tumor's overall oxygenation was altered, whereas the maximum value is determined by the severe hypoxic regions that will be less affected by this treatment. Exposure to high oxygen concentrations at 2.5 hours after tracer injection would prevent further accumulation or reverse tracer binding. For [
18 F]FAZA, preclinical data are available that show reduced uptake after pure oxygen or carbogen breathing in tumor-bearing mice (8, 34) . In our experimental setting only [ 18 F]FMISO showed a lower uptake upon reduced hypoxia. Together with the results of constant accumulation of [ 18 F]FMISO in the tumor over time these data suggest that further accumulation is prevented when reducing the hypoxic fraction. Previous studies observed that [ 18 F]FMISO uptake in squamous cell carcinoma-bearing mice was influenced by the altered breathing condition (35) . These experiments challenged the tracers to their limits and tried to mimic the changing oxygen concentrations in a tumor. It must be kept in mind that these results are influenced by the tumor and animal model chosen and that the tracer metabolism is different in patients. Furthermore, exposing animals to modified oxygen concentration will introduce changes to the whole organism that might influence the distribution and metabolism of the tracer. Our data suggest that [ 18 
Conclusions
In conclusion, all investigated tracers showed different characteristics. The ultimate hypoxia tracer has not been developed, but this and other studies show that hypoxia imaging using the existing tracers gives extra information that can be very useful in the treatment of cancer patients.
